Year |
Citation |
Score |
2020 |
Meng X, Waddington JC, Tailor A, Lister A, Hamlett J, Berry NG, Park K, Sporn M. CDDO-Imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1. Journal of Medicinal Chemistry. PMID 32787104 DOI: 10.1021/Acs.Jmedchem.0C01088 |
0.303 |
|
2019 |
Zhang D, Leal AS, Carapellucci S, Shahani PH, Bhogal JS, Ibrahim S, Raban S, Jurutka PW, Marshall PA, Sporn MB, Wagner CE, Liby KT. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 30760500 DOI: 10.1158/1940-6207.Capr-18-0317 |
0.369 |
|
2019 |
Leal AS, Carapellucci S, ZydecK K, Sporn MB, Liby KT. Abstract LB-186: The rexinoid LG100268 decreases immunosuppressive immune cells and activates T cells in two preclinical models of breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-186 |
0.304 |
|
2017 |
Zhang D, Leal AS, Carapellucci S, Zydeck K, Sporn MB, Liby KT. Chemoprevention of preclinical breast and lung cancer with the bromodomain inhibitor I-BET 762. Cancer Prevention Research (Philadelphia, Pa.). PMID 29246957 DOI: 10.1158/1940-6207.Capr-17-0264 |
0.359 |
|
2017 |
Leal AS, Williams CR, Royce DB, Pioli PA, Sporn MB, Liby KT. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer. Cancer Letters. PMID 28254412 DOI: 10.1016/J.Canlet.2017.02.021 |
0.348 |
|
2017 |
Zhang D, Leal AS, Carapellucci SE, Zydeck K, Chaaban N, Sporn MB, Wagner CE, Liby KT. Abstract 2245: Evaluation of new rexinoids for lung cancer Cancer Research. 77: 2245-2245. DOI: 10.1158/1538-7445.Am2017-2245 |
0.344 |
|
2016 |
Leal AS, Sporn MB, Pioli PA, Liby KT. The triterpenoid CDDO-Imidazolide reduces immune cell infiltration and cytokine secretion in the KrasG12D;Pdx1-Cre mouse (KC) mouse model of pancreatic cancer. Carcinogenesis. PMID 27659181 DOI: 10.1093/Carcin/Bgw099 |
0.304 |
|
2016 |
Liby KT, Sporn MB. Rexinoids for prevention and treatment of cancer: opportunities and challenges. Current Topics in Medicinal Chemistry. PMID 27320330 DOI: 10.2174/1568026616666160617090702 |
0.38 |
|
2015 |
Cao M, Royce DB, Risingsong R, Williams CR, Sporn MB, Liby KT. The rexinoids LG100268 and LG101506 inhibit inflammation and suppress lung carcinogenesis in A/J mice. Cancer Prevention Research (Philadelphia, Pa.). PMID 26554632 DOI: 10.1158/1940-6207.Capr-15-0325 |
0.353 |
|
2015 |
Cao M, Onyango EO, Williams CR, Royce DB, Gribble GW, Sporn MB, Liby KT. Novel Synthetic Pyridyl Analogues of CDDO-Imidazolide Are Useful New Tools in Cancer Prevention. Pharmacological Research : the Official Journal of the Italian Pharmacological Society. PMID 26238177 DOI: 10.1016/J.Phrs.2015.07.024 |
0.354 |
|
2015 |
To C, Ringelberg CS, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis. PMID 25939751 DOI: 10.1093/Carcin/Bgv061 |
0.366 |
|
2015 |
Leal AS, Williams CR, Sporn MB, Liby KT. Abstract A113: Immunomodulatory properties of bromodomain inhibitors in pancreatic cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A113 |
0.351 |
|
2015 |
To C, Royce DB, Williams CR, Risingsong R, Sporn MB, Liby KT. Abstract LB-265: Comparison of oleanane triterpenoids and dimethyl fumarate in lung cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-265 |
0.342 |
|
2015 |
Cao M, Onyango E, Williams C, Royce D, Gribble G, Sporn M, Liby K. Abstract 5559: Novel synthetic pyridyl analogues of CDDO-Im with improved stability and their potential use in cancer prevention Cancer Research. 75: 5559-5559. DOI: 10.1158/1538-7445.Am2015-5559 |
0.392 |
|
2015 |
Leal AS, Williams CR, Sporn MB, Liby KT. Abstract 293: Therapeutic effects of the bromodomain inhibitors JQ1 and I-BET 762 on pancreatic cancer Cancer Research. 75: 293-293. DOI: 10.1158/1538-7445.Am2015-293 |
0.353 |
|
2014 |
So JY, Lin JJ, Wahler J, Liby KT, Sporn MB, Suh N. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. Plos One. 9: e107616. PMID 25229616 DOI: 10.1371/Journal.Pone.0107616 |
0.35 |
|
2014 |
Choi SH, Kim BG, Robinson J, Fink S, Yan M, Sporn MB, Markowitz SD, Letterio JJ. Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis Journal of Clinical Investigation. 124: 2472-2482. PMID 24837432 DOI: 10.1172/Jci69672 |
0.371 |
|
2014 |
Johnson NM, Egner PA, Baxter VK, Sporn MB, Wible RS, Sutter TR, Groopman JD, Kensler TW, Roebuck BD. Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold. Cancer Prevention Research (Philadelphia, Pa.). 7: 658-65. PMID 24662598 DOI: 10.1158/1940-6207.Capr-13-0430 |
0.311 |
|
2014 |
Onyango EO, Fu L, Cao M, Liby KT, Sporn MB, Gribble GW. Synthesis and biological evaluation of amino acid methyl ester conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid against the production of nitric oxide (NO) Bioorganic and Medicinal Chemistry Letters. 24: 532-534. PMID 24388806 DOI: 10.1016/J.Bmcl.2013.12.034 |
0.334 |
|
2014 |
Liby KT, Williams CR, Risingsong R, Sporn MB, Collins RM, Royce DB. Abstract LB-245: The EGRF receptor inhibitor Erlotinib, alone or in combination with the rexinoid LG100268, is effective for prevention in mouse models of lung and pancreatic cancer with Kras mutations Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-245 |
0.313 |
|
2014 |
To C, Williams CR, Royce DB, Collins RM, Sporn MB, Liby KT. Abstract 2965: Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model Cancer Research. 74: 2965-2965. DOI: 10.1158/1538-7445.Am2014-2965 |
0.331 |
|
2013 |
So JY, Wahler JE, Yoon T, Smolarek AK, Lin Y, Shih WJ, Maehr H, Uskokovic M, Liby KT, Sporn MB, Suh N. Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prevention Research (Philadelphia, Pa.). 6: 959-70. PMID 23856074 DOI: 10.1158/1940-6207.Capr-13-0087 |
0.341 |
|
2013 |
Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J. ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Research. 73: 1020-30. PMID 23243027 DOI: 10.1158/0008-5472.Can-12-2862 |
0.352 |
|
2013 |
Tran K, Risingsong R, Royce DB, Williams CR, Sporn MB, Pioli PA, Gediya LK, Njar VC, Liby KT. The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. Carcinogenesis. 34: 199-210. PMID 23042302 DOI: 10.1093/Carcin/Bgs319 |
0.358 |
|
2013 |
Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR, Yamamoto M, Kensler TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxidants & Redox Signaling. 18: 139-57. PMID 22746536 DOI: 10.1089/Ars.2011.4491 |
0.308 |
|
2013 |
So JY, Smolarek AK, Maehr H, Uskokovic M, Liby K, Sporn MB, Suh N. Abstract 180: Inhibition of tumorigenesis by a novel Gemini vitamin D analog BXL0124 and a synthetic triterpenoid CDDO-Im in MMTV-HER2/neu transgenic mice. Cancer Research. 73: 180-180. DOI: 10.1158/1538-7445.Am2013-180 |
0.337 |
|
2012 |
Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacological Reviews. 64: 972-1003. PMID 22966038 DOI: 10.1124/Pr.111.004846 |
0.378 |
|
2012 |
Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nature Reviews. Cancer. 12: 564-71. PMID 22810811 DOI: 10.1038/Nrc3278 |
0.336 |
|
2012 |
Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prevention Research (Philadelphia, Pa.). 5: 726-34. PMID 22401982 DOI: 10.1158/1940-6207.Capr-11-0404 |
0.366 |
|
2012 |
Suh N, Paul S, Lee HJ, Yoon T, Shah N, Son AI, Reddi AH, Medici D, Sporn MB. Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis. Osteoarthritis and Cartilage / Oars, Osteoarthritis Research Society. 20: 446-50. PMID 22343171 DOI: 10.1016/J.Joca.2012.01.018 |
0.32 |
|
2012 |
Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT. CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prevention Research (Philadelphia, Pa.). 5: 89-97. PMID 21933912 DOI: 10.1158/1940-6207.Capr-11-0359 |
0.31 |
|
2011 |
Pareek TK, Belkadi A, Kesavapany S, Zaremba A, Loh SL, Bai L, Cohen ML, Meyer C, Liby KT, Miller RH, Sporn MB, Letterio JJ. Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis. Scientific Reports. 1: 201. PMID 22355716 DOI: 10.1038/Srep00201 |
0.301 |
|
2011 |
Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. The Journal of Clinical Investigation. 121: 4015-29. PMID 21911941 DOI: 10.1172/Jci45862 |
0.327 |
|
2011 |
Yore MM, Kettenbach AN, Sporn MB, Gerber SA, Liby KT. Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR. Plos One. 6: e22862. PMID 21818401 DOI: 10.1371/Journal.Pone.0022862 |
0.664 |
|
2011 |
Kim EH, Deng CX, Sporn MB, Liby KT. CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prevention Research (Philadelphia, Pa.). 4: 425-34. PMID 21372041 DOI: 10.1158/1940-6207.Capr-10-0153 |
0.333 |
|
2011 |
Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress Journal of Natural Products. 74: 537-545. PMID 21309592 DOI: 10.1021/Np100826Q |
0.676 |
|
2011 |
Cantelmo AR, Sogno I, Calò R, Magnani E, Viggiani G, Sporn MB, Albini A. Abstract B76: Synthetic triterpenoids as candidate drugs for cancer prevention and treatment Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-B76 |
0.37 |
|
2011 |
Tran KM, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K. Abstract A103: The synthetic triterpenoid CDDO-methyl ester targets tumor-associated macrophages to delay carcinogenesis in the PyMT model of estrogen receptor negative breast cancer Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A103 |
0.329 |
|
2011 |
Tran KM, Sporn MB, Liby K. Abstract 820: The synthetic triterpenoids, CDDO-methyl ester and CDDO-ethyl amide, and the histone deacetylase inhibitor vorinostat delay carcinogenesis in a transgenic model of estrogen receptor-negative breast cancer Cancer Research. 71: 820-820. DOI: 10.1158/1538-7445.Am2011-820 |
0.312 |
|
2011 |
Liby KT, Royce DB, Risingsong R, Williams CR, Sporn MB. Abstract 2523: Synthetic triterpenoids protect against toxicity and enhance the efficacy of treatment with carboplatin/paclitaxel in experimental lung cancer Cancer Research. 71: 2523-2523. DOI: 10.1158/1538-7445.Am2011-2523 |
0.319 |
|
2011 |
Meyer CJ, Christian Wigley W, Ferguson DA, Warren Huff J, Kral R, Liby KT, Sporn MB. 205 Discovery and Development of Bardoxolone Methyl, an Antioxidant Inflammation Modulator (AIM) Targeting the KEAP1-NRF2 Pathway American Journal of Kidney Diseases. 57: B68. DOI: 10.1053/J.Ajkd.2011.02.208 |
0.352 |
|
2010 |
Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 1427-34. PMID 20959520 DOI: 10.1158/1940-6207.Capr-10-0197 |
0.326 |
|
2010 |
Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology & Medicine. 49: 147-58. PMID 20338236 DOI: 10.1016/J.Freeradbiomed.2010.03.017 |
0.3 |
|
2010 |
Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1812-23. PMID 20215551 DOI: 10.1158/1078-0432.Ccr-09-3272 |
0.34 |
|
2010 |
Honda T, Padegimas EM, David E, Sundararajan C, Liby KT, Williams C, Sporn MB, Visnick M. 2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorganic & Medicinal Chemistry Letters. 20: 2275-8. PMID 20188548 DOI: 10.1016/J.Bmcl.2010.02.007 |
0.304 |
|
2010 |
Liby KT, Royce D, Risingsong R, Williams C, Maitra A, Sporn MB. Abstract 2926: The synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268 extend survival in the KPC transgenic mouse model of pancreatic cancer Cancer Research. 70: 2926-2926. DOI: 10.1158/1538-7445.Am10-2926 |
0.341 |
|
2010 |
Kim E, Sporn MB, Liby KT. Abstract 2509: CDDO-Im induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells Cancer Research. 70: 2509-2509. DOI: 10.1158/1538-7445.Am10-2509 |
0.332 |
|
2010 |
Honda T, Honda Y, Favaloro Jr. FG, Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. ChemInform Abstract: A Novel Dicyanotriterpenoid, 2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, Active at Picomolar Concentrations for Inhibition of Nitric Oxide Production Cheminform. 33: no-no. DOI: 10.1002/chin.200231199 |
0.604 |
|
2009 |
Liby K, Risingsong R, Royce DB, Williams CR, Ma T, Yore MM, Sporn MB. Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice. Cancer Prevention Research (Philadelphia, Pa.). 2: 1050-8. PMID 19952361 DOI: 10.1158/1940-6207.Capr-09-0085 |
0.676 |
|
2009 |
Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. Plos One. 4: e5757. PMID 19484125 DOI: 10.1371/Journal.Pone.0005757 |
0.339 |
|
2009 |
Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis. 30: 1024-31. PMID 19386581 DOI: 10.1093/Carcin/Bgp100 |
0.311 |
|
2009 |
Petronelli A, Saulle E, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Greggi S, Cognetti F, Russo MA, Sporn M, Testa U. High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. Cancer Letters. 282: 214-28. PMID 19364626 DOI: 10.1016/J.Canlet.2009.03.018 |
0.329 |
|
2009 |
Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Molecules and Cells. 27: 279-82. PMID 19326073 DOI: 10.1007/S10059-009-0050-Y |
0.313 |
|
2009 |
Sogno I, Vannini N, Lorusso G, Cammarota R, Noonan DM, Generoso L, Sporn MB, Albini A. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 181: 209-12. PMID 19213570 DOI: 10.1007/978-3-540-69297-3_19 |
0.361 |
|
2009 |
Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El-Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proceedings of the National Academy of Sciences of the United States of America. 106: 250-5. PMID 19104057 DOI: 10.1073/Pnas.0804333106 |
0.306 |
|
2008 |
Subba Rao GS, Kondaiah P, Singh SK, Ravanan P, Sporn MB. Chemical modifications of natural triterpenes - glycyrrhetinic and boswellic acids: evaluation of their biological activity. Tetrahedron. 64: 11541-11548. PMID 20622928 DOI: 10.1016/J.Tet.2008.10.035 |
0.311 |
|
2008 |
Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression. Arthritis Research & Therapy. 10: R139. PMID 19046432 DOI: 10.1186/Ar2564 |
0.31 |
|
2008 |
Venè R, Larghero P, Arena G, Sporn MB, Albini A, Tosetti F. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Research. 68: 6987-96. PMID 18757413 DOI: 10.1158/0008-5472.Can-07-6362 |
0.344 |
|
2008 |
Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, Yoshizawa H, Gribble GW, Williams CR, Risingsong R, Royce DB, Dinkova-Kostova AT, Stephenson KK, Egner PA, Yates MS, ... ... Sporn MB, et al. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin Cancer Research. 68: 6727-6733. PMID 18701497 DOI: 10.1158/0008-5472.Can-08-1123 |
0.688 |
|
2008 |
Marhenke S, Lamlé J, Buitrago-Molina LE, Cañón JM, Geffers R, Finegold M, Sporn M, Yamamoto M, Manns MP, Grompe M, Vogel A. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology (Baltimore, Md.). 48: 487-96. PMID 18666252 DOI: 10.1002/Hep.22391 |
0.313 |
|
2008 |
Liby K, Risingsong R, Royce DB, R. Williams C, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB. Prevention and treatment of experimental estrogen receptor- negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268 Clinical Cancer Research. 14: 4556-4563. PMID 18628471 DOI: 10.1158/1078-0432.Ccr-08-0040 |
0.664 |
|
2008 |
Liby K, Black CC, Royce DB, Williams CR, Risingsong R, Yore MM, Liu X, Honda T, Gribble GW, Lamph WW, Sporn TA, Dmitrovsky E, Sporn MB. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis Molecular Cancer Therapeutics. 7: 1251-1257. PMID 18483313 DOI: 10.1158/1535-7163.Mct-08-0023 |
0.667 |
|
2008 |
Tran TA, McCoy MK, Sporn MB, Tansey MG. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. Journal of Neuroinflammation. 5: 14. PMID 18474101 DOI: 10.1186/1742-2094-5-14 |
0.328 |
|
2008 |
Osburn WO, Yates MS, Dolan PD, Chen S, Liby KT, Sporn MB, Taguchi K, Yamamoto M, Kensler TW. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicological Sciences : An Official Journal of the Society of Toxicology. 104: 218-27. PMID 18417483 DOI: 10.1093/Toxsci/Kfn079 |
0.311 |
|
2008 |
To C, Kulkarni S, Pawson T, Honda T, Gribble GW, Sporn MB, Wrana JL, Di Guglielmo GM. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor β-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex Journal of Biological Chemistry. 283: 11700-11713. PMID 18283107 DOI: 10.1074/Jbc.M704064200 |
0.367 |
|
2008 |
Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS. Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO. Cancer Biology & Therapy. 7: 709-17. PMID 18277094 DOI: 10.4161/Cbt.7.5.5713 |
0.359 |
|
2008 |
Dinkova-Kostova AT, Jenkins SN, Wehage SL, Huso DL, Benedict AL, Stephenson KK, Fahey JW, Liu H, Liby KT, Honda T, Gribble GW, Sporn MB, Talalay P. A dicyanotriterpenoid induces cytoprotective enzymes and reduces multiplicity of skin tumors in UV-irradiated mice Biochemical and Biophysical Research Communications. 367: 859-865. PMID 18206646 DOI: 10.1016/J.Bbrc.2008.01.026 |
0.301 |
|
2007 |
Zou W, Chen S, Liu X, Yue P, Sporn MB, Khuri FR, Sun SY. c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biology & Therapy. 6: 1614-20. PMID 18253090 DOI: 10.4161/Cbt.6.10.4763 |
0.34 |
|
2007 |
Vannini N, Lorusso G, Cammarota R, Barberis M, Noonan DM, Sporn MB, Albini A. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Molecular Cancer Therapeutics. 6: 3139-46. PMID 18065492 DOI: 10.1158/1535-7163.Mct-07-0451 |
0.374 |
|
2007 |
Liby K, Royce DB, Risingsong R, Williams CR, Wood MD, Chandraratna RA, Sporn MB. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6237-43. PMID 17947492 DOI: 10.1158/1078-0432.Ccr-07-1342 |
0.319 |
|
2007 |
Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C, Traore K, Bream JH, Trush MA, Liby KT, Sporn MB, Kensler TW, Biswal S. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxidants & Redox Signaling. 9: 1963-70. PMID 17822364 DOI: 10.1089/Ars.2007.1745 |
0.328 |
|
2007 |
Koschmieder S, D'Alò F, Radomska H, Schöneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, ... ... Sporn MB, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 110: 3695-705. PMID 17671235 DOI: 10.1182/Blood-2006-11-058941 |
0.324 |
|
2007 |
Liby K, Honda T, Williams CR, Risingsong R, Royce DB, Suh N, Dinkova-Kostova AT, Stephenson KK, Talalay P, Sundararajan C, Gribble GW, Sporn MB. Novel semisynthetic analogues of betulinic acid with diverse cytoprotective, antiproliferative, and proapoptotic activities Molecular Cancer Therapeutics. 6: 2113-2119. PMID 17620440 DOI: 10.1158/1535-7163.Mct-07-0180 |
0.39 |
|
2007 |
Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Reviews. Cancer. 7: 357-69. PMID 17446857 DOI: 10.1038/Nrc2129 |
0.675 |
|
2007 |
Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB. The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice Cancer Research. 67: 2414-2419. PMID 17363558 DOI: 10.1158/0008-5472.Can-06-4534 |
0.689 |
|
2007 |
Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Molecular Cancer Therapeutics. 6: 154-62. PMID 17237276 DOI: 10.1158/1535-7163.Mct-06-0516 |
0.345 |
|
2007 |
Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nature Reviews. Cancer. 7: 139-47. PMID 17218951 DOI: 10.1038/Nrc2067 |
0.302 |
|
2007 |
Sporn MB, Liby K, Yore MM, Suh N, Albini A, Honda T, Sundararajan C, Gribble GW. Platforms and networks in triterpenoid pharmacology Drug Development Research. 68: 174-182. DOI: 10.1002/Ddr.20179 |
0.662 |
|
2006 |
Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Molecular Cancer Therapeutics. 5: 3232-9. PMID 17148759 DOI: 10.1158/1535-7163.Mct-06-0444 |
0.693 |
|
2006 |
Thimmulappa RK, Scollick C, Traore K, Yates M, Trush MA, Liby KT, Sporn MB, Yamamoto M, Kensler TW, Biswal S. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochemical and Biophysical Research Communications. 351: 883-9. PMID 17097057 DOI: 10.1016/J.Bbrc.2006.10.102 |
0.301 |
|
2006 |
Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5902-9. PMID 17020999 DOI: 10.1158/1078-0432.Ccr-06-1119 |
0.661 |
|
2006 |
Honda T, Liby KT, Su X, Sundararajan C, Honda Y, Suh N, Risingsong R, Williams CR, Royce DB, Sporn MB, Gribble GW. Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A. Bioorganic & Medicinal Chemistry Letters. 16: 6306-9. PMID 16996735 DOI: 10.1016/J.Bmcl.2006.09.012 |
0.327 |
|
2006 |
Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4288-93. PMID 16857804 DOI: 10.1158/1078-0432.Ccr-06-0215 |
0.363 |
|
2006 |
Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, Sporn M, Suh N. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Molecular Cancer Therapeutics. 5: 1452-8. PMID 16818503 DOI: 10.1158/1535-7163.Mct-06-0136 |
0.384 |
|
2006 |
Han SS, Peng L, Chung ST, DuBois W, Maeng SH, Shaffer AL, Sporn MB, Janz S. CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. Molecular Cancer. 5: 22. PMID 16759389 DOI: 10.1186/1476-4598-5-22 |
0.322 |
|
2006 |
Yates MS, Kwak MK, Egner PA, Groopman JD, Bodreddigari S, Sutter TR, Baumgartner KJ, Roebuck BD, Liby KT, Yore MM, Honda T, Gribble GW, Sporn MB, Kensler TW. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Research. 66: 2488-94. PMID 16489057 DOI: 10.1158/0008-5472.Can-05-3823 |
0.666 |
|
2006 |
Couch RD, Ganem NJ, Zhou M, Popov VM, Honda T, Veenstra TD, Sporn MB, Anderson AC. 2-cyano-3,12-dioxooleana-1,9(11)-diene-28-oic acid disrupts microtubule polymerization: a possible mechanism contributing to apoptosis. Molecular Pharmacology. 69: 1158-65. PMID 16407469 DOI: 10.1124/Mol.105.018572 |
0.355 |
|
2006 |
Sporn MB. The early history of TGF-beta, and a brief glimpse of its future. Cytokine & Growth Factor Reviews. 17: 3-7. PMID 16290110 DOI: 10.1016/J.Cytogfr.2005.09.012 |
0.34 |
|
2005 |
Sporn MB, Liby KT. Cancer chemoprevention: scientific promise, clinical uncertainty. Nature Clinical Practice. Oncology. 2: 518-25. PMID 16205771 DOI: 10.1038/Ncponc0319 |
0.325 |
|
2005 |
Samudio I, Konopleva M, Hail N, Shi YX, McQueen T, Hsu T, Evans R, Honda T, Gribble GW, Sporn M, Gilbert HF, Safe S, Andreeff M. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer. The Journal of Biological Chemistry. 280: 36273-82. PMID 16118208 DOI: 10.1074/Jbc.M507518200 |
0.333 |
|
2005 |
Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Research. 65: 4799-808. PMID 15930300 DOI: 10.1158/0008-5472.Can-04-3319 |
0.355 |
|
2005 |
Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, Williams CR, Royce DB, Honda T, Honda Y, Gribble GW, Hill-Kapturczak N, Agarwal A, Sporn MB. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Research. 65: 4789-98. PMID 15930299 DOI: 10.1158/0008-5472.Can-04-4539 |
0.773 |
|
2005 |
Couch RD, Browning RG, Honda T, Gribble GW, Wright DL, Sporn MB, Anderson AC. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorganic & Medicinal Chemistry Letters. 15: 2215-9. PMID 15837296 DOI: 10.1016/J.Bmcl.2005.03.031 |
0.324 |
|
2005 |
Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress Proceedings of the National Academy of Sciences of the United States of America. 102: 4584-4589. PMID 15767573 DOI: 10.1073/Pnas.0500815102 |
0.331 |
|
2005 |
Ikeda T, Kimura F, Nakata Y, Sato K, Ogura K, Motoyoshi K, Sporn M, Kufe D. Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells. Cell Death and Differentiation. 12: 523-31. PMID 15746941 DOI: 10.1038/Sj.Cdd.4401574 |
0.336 |
|
2005 |
Konopleva M, Samudio I, Tsao T, Kornblau SM, Shi Y, McQueen T, Contractor R, Sporn MB, Meyer CJ, Huff W, Safe SH, Kantarjian H, Andreeff M. Mechanisms and Activity of PPARγ-Active Triterpenoids CDDO and CDDO-Me in Leukemias. Blood. 106: 2460-2460. DOI: 10.1182/Blood.V106.11.2460.2460 |
0.383 |
|
2005 |
Koschmieder S, D′Alo′ F, Radomska H, Kobayashi S, Levantini E, Suh N, Sporn MB, Di Ruscio A, Voso MT, Berdel WE, Müller-Tidow C, Serve H, Tenen DG. CDDO Increases Translation of CCAAT Enhancer Binding Protein alpha To Induce Granulocytic Differentiation. Blood. 106: 2458-2458. DOI: 10.1182/Blood.V106.11.2458.2458 |
0.322 |
|
2004 |
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Research. 64: 7570-8. PMID 15492284 DOI: 10.1158/0008-5472.Can-04-1238 |
0.329 |
|
2004 |
Honda T, Janosik T, Honda Y, Han J, Liby KT, Williams CR, Couch RD, Anderson AC, Sporn MB, Gribble GW. Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets. Journal of Medicinal Chemistry. 47: 4923-32. PMID 15369396 DOI: 10.1021/Jm049727E |
0.33 |
|
2004 |
Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Research. 64: 3566-71. PMID 15150113 DOI: 10.1158/0008-5472.Can-04-0234 |
0.706 |
|
2004 |
Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2570-7. PMID 15073138 DOI: 10.1158/1078-0432.Ccr-03-0271 |
0.666 |
|
2004 |
Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 103: 3158-66. PMID 15070698 DOI: 10.1182/Blood-2003-08-2873 |
0.32 |
|
2004 |
Mix KS, Coon CI, Rosen ED, Suh N, Sporn MB, Brinckerhoff CE. Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling. Molecular Pharmacology. 65: 309-18. PMID 14742672 DOI: 10.1124/Mol.65.2.309 |
0.347 |
|
2004 |
Hail N, Konopleva M, Sporn M, Lotan R, Andreeff M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO). The Journal of Biological Chemistry. 279: 11179-87. PMID 14711815 DOI: 10.1074/Jbc.M312758200 |
0.307 |
|
2003 |
Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL Leukemia. 17: 2122-2129. PMID 12931220 DOI: 10.1038/Sj.Leu.2403112 |
0.304 |
|
2003 |
Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 2798-806. PMID 12855660 |
0.676 |
|
2003 |
Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Research. 63: 1371-6. PMID 12649201 |
0.656 |
|
2002 |
Favaloro FG, Honda T, Honda Y, Gribble GW, Suh N, Risingsong R, Sporn MB. Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages. Journal of Medicinal Chemistry. 45: 4801-5. PMID 12383005 DOI: 10.1021/Jm025565F |
0.324 |
|
2002 |
Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 100: 2965-72. PMID 12351409 DOI: 10.1182/Blood-2002-04-1174 |
0.32 |
|
2002 |
Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. The Journal of Biological Chemistry. 277: 22320-9. PMID 11940602 DOI: 10.1074/Jbc.M202458200 |
0.336 |
|
2002 |
Honda T, Honda Y, Favaloro FG, Gribble GW, Suh N, Place AE, Rendi MH, Sporn MB. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorganic & Medicinal Chemistry Letters. 12: 1027-30. PMID 11909709 DOI: 10.1016/S0960-894X(02)00105-1 |
0.765 |
|
2002 |
Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. The Journal of Biological Chemistry. 277: 16448-55. PMID 11880365 DOI: 10.1074/Jbc.M108974200 |
0.333 |
|
2002 |
Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, ... Sporn MB, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 99: 326-35. PMID 11756188 DOI: 10.1182/Blood.V99.1.326 |
0.342 |
|
2001 |
Suh N, Glasebrook AL, Palkowitz AD, Bryant HU, Burris LL, Starling JJ, Pearce HL, Williams C, Peer C, Wang Y, Sporn MB. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Research. 61: 8412-5. PMID 11731420 |
0.435 |
|
2001 |
Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs) Trends in Molecular Medicine. 7: 395-400. PMID 11530334 DOI: 10.1016/S1471-4914(01)02100-1 |
0.351 |
|
2000 |
Honda T, Rounds BV, Bore L, Finlay HJ, Favaloro FG, Suh N, Wang Y, Sporn MB, Gribble GW. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Journal of Medicinal Chemistry. 43: 4233-46. PMID 11063620 DOI: 10.1021/Jm0002230 |
0.515 |
|
2000 |
Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM, Plunket KD, Mangelsdorf DJ, Blanchard SG, Willson TM, Sporn MB. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Molecular Endocrinology (Baltimore, Md.). 14: 1550-6. PMID 11043571 DOI: 10.1210/Mend.14.10.0545 |
0.499 |
|
2000 |
Honda T, Gribble GW, Suh N, Finlay HJ, Rounds BV, Bore L, Favaloro FG, Wang Y, Sporn MB. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. Journal of Medicinal Chemistry. 43: 1866-77. PMID 10794703 DOI: 10.1021/Jm000008J |
0.522 |
|
2000 |
Sporn MB, Suh N. Chemoprevention of cancer Carcinogenesis. 21: 525-530. PMID 10688873 DOI: 10.1093/Carcin/21.3.525 |
0.308 |
|
1999 |
Sporn MB. TGF-β: 20 years and counting Microbes and Infection. 1: 1251-1253. PMID 10611752 DOI: 10.1016/S1286-4579(99)00260-9 |
0.327 |
|
1999 |
Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Research. 59: 5671-3. PMID 10582681 |
0.444 |
|
1999 |
Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, ... ... Sporn MB, et al. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Research. 59: 336-41. PMID 9927043 |
0.722 |
|
1998 |
Honda T, Rounds BV, Gribble GW, Suh N, Wang Y, Sporn MB. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorganic & Medicinal Chemistry Letters. 8: 2711-4. PMID 9873608 DOI: 10.1016/S0960-894X(98)00479-X |
0.518 |
|
1998 |
Burmester JK, Qian SW, Ohlsen D, Phan S, Sporn MB, Roberts AB. Mutational analysis of a transforming growth factor-beta receptor binding site. Growth Factors (Chur, Switzerland). 15: 231-42. PMID 9570043 DOI: 10.3109/08977199809002119 |
0.349 |
|
1998 |
Lucia MS, Sporn MB, Roberts AB, Stewart LV, Danielpour D. The role of transforming growth factor-β1, -β2, and -β3 in androgen-responsive growth of NRP-152 rat prostatic epithelial cells Journal of Cellular Physiology. 175: 184-192. PMID 9525477 DOI: 10.1002/(Sici)1097-4652(199805)175:2<184::Aid-Jcp8>3.0.Co;2-K |
0.326 |
|
1997 |
Hong WK, Sporn MB. Recent advances in chemoprevention of cancer Science. 278: 1073-1077. PMID 9353183 DOI: 10.1126/Science.278.5340.1073 |
0.35 |
|
1997 |
Finlay HJ, Honda T, Gribble GW, Danielpour D, Benoit NE, Suh N, Williams C, Sporn MB. Novel A-ring cleaved analogs of oleanolic and ursolic acids which affect growth regulation in NRP.152 prostate cells Bioorganic and Medicinal Chemistry Letters. 7: 1769-1772. DOI: 10.1016/S0960-894X(97)00310-7 |
0.317 |
|
1997 |
Honda T, Finlay HJ, Gribble GW, Suh N, Sporn MB. New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages Bioorganic & Medicinal Chemistry Letters. 7: 1623-1628. DOI: 10.1016/S0960-894X(97)00279-5 |
0.314 |
|
1996 |
Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QW, Smith TW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. The Journal of Experimental Medicine. 184: 1425-33. PMID 8879214 DOI: 10.1084/Jem.184.4.1425 |
0.308 |
|
1996 |
Hinck AP, Archer SJ, Qian SW, Roberts AB, Sporn MB, Weatherbee JA, Tsang ML, Lucas R, Zhang BL, Wenker J, Torchia DA. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry. 35: 8517-34. PMID 8679613 DOI: 10.1021/Bi9604946 |
0.314 |
|
1996 |
Böttinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, Wakefield LM, Roberts AB, Thorgeirsson SS, Sporn MB. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America. 93: 5877-82. PMID 8650186 DOI: 10.1073/Pnas.93.12.5877 |
0.369 |
|
1996 |
Vodovotz Y, Geiser AG, Chesler L, Letterio JJ, Campbell A, Lucia MS, Sporn MB, Roberts AB. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. The Journal of Experimental Medicine. 183: 2337-42. PMID 8642342 DOI: 10.1084/Jem.183.5.2337 |
0.372 |
|
1996 |
Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. Journal of the National Cancer Institute. 88: 123-5. PMID 8537973 DOI: 10.1093/Jnci/88.2.123 |
0.317 |
|
1996 |
Bae HW, Geiser AG, Kim DH, Chung MT, Burmester JK, Sporn MB, Roberts AB, Kim SJ. Characterization of the promoter region of the human transforming growth factor-beta type II receptor gene. The Journal of Biological Chemistry. 270: 29460-8. PMID 7493985 DOI: 10.1074/Jbc.270.49.29460 |
0.345 |
|
1995 |
Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proceedings of the National Academy of Sciences of the United States of America. 92: 2572-6. PMID 7708687 DOI: 10.1073/Pnas.92.7.2572 |
0.355 |
|
1994 |
Muir GH, Butta A, Shearer RJ, Fisher C, Dearnaley DP, Flanders KC, Sporn MB, Colletta AA. Induction of transforming growth factor β in hormonally treated human prostate cancer British Journal of Cancer. 69: 130-134. PMID 8286194 DOI: 10.1038/Bjc.1994.21 |
0.326 |
|
1994 |
Ballock RT, Heydemann A, Wakefield LM, Flanders KC, Roberts AB, Sporn MB. Inhibition of the chondrocyte phenotype by retinoic acid involves upregulation of metalloprotease genes independent of TGF-beta. Journal of Cellular Physiology. 159: 340-6. PMID 8163572 DOI: 10.1002/Jcp.1041590217 |
0.367 |
|
1994 |
Jakowlew SB, Ciment G, Tuan RS, Sporn MB, Roberts AB. Expression of transforming growth factor-beta 2 and beta 3 mRNAs and proteins in the developing chicken embryo. Differentiation; Research in Biological Diversity. 55: 105-18. PMID 8143928 DOI: 10.1046/J.1432-0436.1994.5520105.X |
0.322 |
|
1994 |
Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, Sporn MB. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proceedings of the National Academy of Sciences of the United States of America. 91: 8772-6. PMID 8090721 DOI: 10.1073/Pnas.91.19.8772 |
0.364 |
|
1994 |
Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher FJ, Kim SJ. Repression of the transforming growth factor-β1 gene by the Wilms' tumor suppressor WT1 gene product Molecular Endocrinology. 8: 595-602. PMID 8058069 DOI: 10.1210/Mend.8.5.8058069 |
0.332 |
|
1994 |
Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, Baird A. Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. The European Journal of Neuroscience. 6: 355-63. PMID 8019673 DOI: 10.1111/J.1460-9568.1994.Tb00278.X |
0.356 |
|
1994 |
Letterio JJ, Geiser AG, Kulkarni AB, Roche NS, Sporn MB, Roberts AB. Maternal rescue of transforming growth factor-beta 1 null mice. Science (New York, N.Y.). 264: 1936-8. PMID 8009224 DOI: 10.1126/Science.8009224 |
0.344 |
|
1994 |
Qian SW, Burmester JK, Sun PD, Huang A, Ohlsen DJ, Suardet L, Flanders KC, Davies D, Roberts AB, Sporn MB. Characterization of mutated transforming growth factor-beta s which possess unique biological properties. Biochemistry. 33: 12298-304. PMID 7918451 DOI: 10.1021/Bi00206A037 |
0.363 |
|
1993 |
Hunter KE, Sporn MB, Davies AM. Transforming growth factor-betas inhibit mitogen-stimulated proliferation of astrocytes Glia. 7: 203-211. PMID 8454307 DOI: 10.1002/Glia.440070303 |
0.359 |
|
1993 |
Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-β (TGF-β Growth Factors. 8: 1-9. PMID 8448037 DOI: 10.3109/08977199309029129 |
0.346 |
|
1993 |
Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proceedings of the National Academy of Sciences of the United States of America. 90: 770-4. PMID 8421714 DOI: 10.1073/Pnas.90.2.770 |
0.374 |
|
1993 |
Ballock RT, Heydemann A, Wakefield LM, Flanders KC, Roberts AB, Sporn MB. TGF-beta 1 prevents hypertrophy of epiphyseal chondrocytes: regulation of gene expression for cartilage matrix proteins and metalloproteases. Developmental Biology. 158: 414-29. PMID 8344460 DOI: 10.1006/Dbio.1993.1200 |
0.368 |
|
1993 |
Flanders KC, Winokur TS, Holder MG, Sporn MB. Hyperthemia induces experssion of transforming growth factor-βs in rat cardiac cells in vitro and in vivo Journal of Clinical Investigation. 92: 404-410. PMID 8326008 DOI: 10.1172/Jci116581 |
0.306 |
|
1993 |
Geiser AG, Busam KJ, Kim SJ, Lafyatis R, O'Reilly MA, Webbink R, Roberts AB, Sporn MB. Regulation of the transforming growth factor-beta 1 and -beta 3 promoters by transcription factor Sp1. Gene. 129: 223-8. PMID 8325508 DOI: 10.1016/0378-1119(93)90272-5 |
0.334 |
|
1993 |
Geiser AG, Letterio JJ, Kulkarni AB, Karlsson S, Roberts AB, Sporn MB. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proceedings of the National Academy of Sciences of the United States of America. 90: 9944-8. PMID 8234339 DOI: 10.1073/Pnas.90.21.9944 |
0.354 |
|
1993 |
Burmester JK, Su Wen Qian, Roberts AB, Huang A, Amatayakul-Chantler S, Suardet L, Odartchenko N, Madri JA, Sporn MB. Characterization of distinct functional domains of transforming growth factor β Proceedings of the National Academy of Sciences of the United States of America. 90: 8628-8632. PMID 7690965 DOI: 10.1073/Pnas.90.18.8628 |
0.36 |
|
1993 |
Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson S, Yuspa SH. Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proceedings of the National Academy of Sciences of the United States of America. 90: 6076-80. PMID 7687059 DOI: 10.1073/Pnas.90.13.6076 |
0.357 |
|
1993 |
Jakowlew SB, Ciment G, Tuan RS, Sporn MB, Roberts AB. Pattern of expression of transforming growth factor-beta 4 mRNA and protein in the developing chicken embryo. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 195: 276-89. PMID 1304823 DOI: 10.1002/Aja.1001950406 |
0.317 |
|
1993 |
Roberts AB, Sporn MB, Lefer AM. Cardioprotective actions of transforming growth factor-β Trends in Cardiovascular Medicine. 3: 77-81. DOI: 10.1016/1050-1738(93)90027-4 |
0.347 |
|
1992 |
Noma T, Glick AB, Geiser AG, O'Reilly MA, Miller J, Roberts AB, Sporn MB. Molecular cloning and structure of the human transforming growth factor-beta 2 gene promoter. Growth Factors (Chur, Switzerland). 4: 247-55. PMID 1764261 DOI: 10.3109/08977199109043910 |
0.342 |
|
1992 |
Lafyatis R, Denhez F, Williams T, Sporn M, Roberts A. Sequence specific protein binding to and activation of the TGF-beta 3 promoter through a repeated TCCC motif. Nucleic Acids Research. 19: 6419-25. PMID 1754378 DOI: 10.1093/Nar/19.23.6419 |
0.352 |
|
1992 |
Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MB. Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience. 44: 613-25. PMID 1754055 DOI: 10.1016/0306-4522(91)90082-Y |
0.331 |
|
1992 |
Jakowlew SB, Cubert J, Danielpour D, Sporn MB, Roberts AB. Differential regulation of the expression of transforming growth factor-β mRNAs by growth factors and retinoic acid in chicken embryo chondrocytes, myocytes, and fibroblasts Journal of Cellular Physiology. 150: 377-385. PMID 1734039 DOI: 10.1002/Jcp.1041500222 |
0.354 |
|
1992 |
Wakefield LM, Kondaiah P, Hollands RS, Winokur TS, Sporn MB. Addition of a C-terminal extension sequence to transforming growth factor-beta 1 interferes with biosynthetic processing and abolishes biological activity. Growth Factors (Chur, Switzerland). 5: 243-53. PMID 1663772 DOI: 10.3109/08977199109000288 |
0.359 |
|
1992 |
Roberts AB, Sporn MB. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues Molecular Reproduction and Development. 32: 91-98. PMID 1637557 DOI: 10.1002/Mrd.1080320203 |
0.342 |
|
1992 |
Su Wen Qian, Burmester JK, Merwin JR, Madri JA, Sporn MB, Roberts AB. Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor β on endothelial cells Proceedings of the National Academy of Sciences of the United States of America. 89: 6290-6294. PMID 1631120 DOI: 10.1073/Pnas.89.14.6290 |
0.36 |
|
1992 |
Roberts AB, McCune BK, Sporn MB. TGF-β: Regulation of extracellular matrix Kidney International. 41: 557-559. PMID 1573828 DOI: 10.1038/Ki.1992.81 |
0.342 |
|
1992 |
McCune BK, Mullin BR, Flanders KC, Jaffurs WJ, Mullen LT, Sporn MB. Localization of transforming growth factor-beta isotypes in lesions of the human breast. Human Pathology. 23: 13-20. PMID 1544664 DOI: 10.1016/0046-8177(92)90004-M |
0.363 |
|
1992 |
Logan A, Frautschy SA, Gonzalez AM, Sporn MB, Baird A. Enhanced expression of transforming growth factor beta 1 in the rat brain after a localized cerebral injury. Brain Research. 587: 216-25. PMID 1525658 DOI: 10.1016/0006-8993(92)91000-5 |
0.345 |
|
1992 |
Sporn MB, Roberts AB. Autocrine secretion - 10 Years later Annals of Internal Medicine. 117: 408-414. PMID 1503333 DOI: 10.7326/0003-4819-117-5-408 |
0.321 |
|
1992 |
Roberts AB, Roche NS, Winokur TS, Burmester JK, Sporn MB. Role of transforming growth factor-beta in maintenance of function of cultured neonatal cardiac myocytes. Autocrine action and reversal of damaging effects of interleukin-1. The Journal of Clinical Investigation. 90: 2056-62. PMID 1430228 DOI: 10.1172/Jci116087 |
0.343 |
|
1992 |
Jakowlew SB, Lechleider R, Geiser AG, Kim SJ, Santa-Coloma TA, Cubert J, Sporn MB, Roberts AB. Identification and characterization of the chicken transforming growth factor-beta 3 promoter. Molecular Endocrinology (Baltimore, Md.). 6: 1285-98. PMID 1406706 DOI: 10.1210/Mend.6.8.1406706 |
0.353 |
|
1992 |
Pinar H, Thompson NL, Flanders KC, Sporn MB, Sung J, Rogers BB. Distribution of transforming growth factor beta in a two-week-old human embryo. Growth Factors (Chur, Switzerland). 6: 203-8. PMID 1389226 DOI: 10.3109/08977199209026927 |
0.301 |
|
1992 |
O'reilly MA, Danielpour D, Roberts AB, Sporn MB. Regulation of expression of transforming growth factor-β2 by transforming growth factor-β isoforms is dependent upon cell type Growth Factors. 6: 193-201. PMID 1389225 DOI: 10.3109/08977199209026926 |
0.321 |
|
1992 |
Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proceedings of the National Academy of Sciences of the United States of America. 89: 421-5. PMID 1370356 DOI: 10.1073/Pnas.89.1.421 |
0.381 |
|
1992 |
Wakefield LM, Colletta AA, McCune BK, Sporn MB. Roles for transforming growth factors-beta in the genesis, prevention, and treatment of breast cancer Cancer Treatment and Research. 61: 97-136. PMID 1360247 DOI: 10.1007/978-1-4615-3500-3_6 |
0.366 |
|
1992 |
Sporn MB, Roberts AB. Transforming growth factor-β: Recent progress and new challenges Journal of Cell Biology. 119: 1017-1022. PMID 1332976 DOI: 10.1083/Jcb.119.5.1017 |
0.307 |
|
1992 |
Roberts AB, Vodovotz Y, Roche NS, Sporn MB, Nathan CF. Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 beta on the beating rate of cultured cardiac myocytes. Molecular Endocrinology (Baltimore, Md.). 6: 1921-30. PMID 1282674 DOI: 10.1210/Mend.6.11.1282674 |
0.343 |
|
1991 |
Wakefield L, Kim SJ, Glick A, Winokur T, Colletta A, Sporn M. Regulation of transforming growth factor-beta subtypes by members of the steroid hormone superfamily. Journal of Cell Science. Supplement. 13: 139-48. PMID 2084113 DOI: 10.1242/Jcs.1990.Supplement_13.13 |
0.382 |
|
1991 |
Glick AB, Sporn MB, Yuspa SH. Altered regulation of TGF-β1 and TGF-α in primary keratinocytes and papillomas expressing v-Ha-ras Molecular Carcinogenesis. 4: 210-219. PMID 2064727 DOI: 10.1002/Mc.2940040308 |
0.318 |
|
1991 |
Sporn MB, Roberts AB. Interactions of retinoids and transforming growth factor-β in regulation of cell differentiation and proliferation Molecular Endocrinology. 5: 3-7. PMID 2017191 DOI: 10.1210/Mend-5-1-3 |
0.345 |
|
1991 |
Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. The Journal of Clinical Investigation. 87: 277-83. PMID 1985102 DOI: 10.1172/Jci114983 |
0.404 |
|
1991 |
Jakowlew SB, Dillard PJ, Winokur TS, Flanders KC, Sporn MB, Roberts AB. Expression of transforming growth factor-beta s 1-4 in chicken embryo chondrocytes and myocytes. Developmental Biology. 143: 135-48. PMID 1985015 DOI: 10.1016/0012-1606(91)90061-7 |
0.33 |
|
1991 |
Kim SJ, Lafyatis R, Kim KY, Angel P, Fujiki H, Karin M, Sporn MB, Roberts AB. Regulation of collagenase gene expression by okadaic acid, an inhibitor of protein phosphatases. Cell Regulation. 1: 269-78. PMID 1966042 DOI: 10.1091/Mbc.1.3.269 |
0.302 |
|
1991 |
Kim SJ, Winokur TS, Lee HD, Danielpour D, Kim KY, Geiser AG, Chen LS, Sporn MB, Roberts AB, Jay G. Overexpression of transforming growth factor-β in transgenic mice carrying the human T-cell lymphotropic virus type I tax gene Molecular and Cellular Biology. 11: 5222-5228. PMID 1922042 DOI: 10.1128/Mcb.11.10.5222 |
0.341 |
|
1991 |
Kim SJ, Lee HD, Robbins PD, Busam K, Sporn MB, Roberts AB. Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. Proceedings of the National Academy of Sciences of the United States of America. 88: 3052-6. PMID 1901652 DOI: 10.1073/Pnas.88.8.3052 |
0.383 |
|
1991 |
Heine UI, Burmester JK, Flanders KC, Danielpour D, Munoz EF, Roberts AB, Sporn MB. Localization of transforming growth factor-beta 1 in mitochondria of murine heart and liver Cell Regulation. 2: 467-477. PMID 1883875 DOI: 10.1091/Mbc.2.6.467 |
0.337 |
|
1991 |
Danielpour D, Kim KY, Winokur TS, Sporn MB. Differential regulation of the expression of transforming growth factor-βs 1 and 2 by retinoic acid, epidermal growth factor, and dexamethasone in NRK-49F and A549 cells Journal of Cellular Physiology. 148: 235-244. PMID 1880152 DOI: 10.1002/Jcp.1041480208 |
0.338 |
|
1991 |
Qian SW, Kondaiah P, Casscells W, Roberts AB, Sporn MB. A second messenger RNA species of transforming growth factor beta 1 in infarcted rat heart. Cell Regulation. 2: 241-9. PMID 1859854 DOI: 10.1091/Mbc.2.3.241 |
0.319 |
|
1991 |
Horikoshi S, McCune BK, Ray PE, Kopp JB, Sporn MB, Klotman PE. Water deprivation stimulates transforming growth factor-β2 accumulation in the juxtaglomerular apparatus of mouse kidney Journal of Clinical Investigation. 88: 2117-2122. PMID 1752966 DOI: 10.1172/Jci115541 |
0.314 |
|
1991 |
Crowther D, Sporn MB, Roberts AB, Durie BGM. Workshop on Growth Factors Annals of Oncology. 2: 207-211. PMID 1675582 DOI: 10.1093/Annonc/2.Suppl_2.207 |
0.329 |
|
1990 |
Van Obberghen-Schilling E, Kondaiah P, Ludwig RL, Sporn MB, Baker CC. Complementary deoxyribonucleic acid cloning of bovine transforming growth factor-beta 1. Molecular Endocrinology (Baltimore, Md.). 1: 693-8. PMID 3153459 DOI: 10.1210/Mend-1-10-693 |
0.345 |
|
1990 |
Wakefield LM, Smith DM, Broz S, Jackson M, Levinson AD, Sporn MB. Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors (Chur, Switzerland). 1: 203-18. PMID 2629880 DOI: 10.3109/08977198908997997 |
0.333 |
|
1990 |
Flanders KC, Cissel DS, Mullen LT, Danielpour D, Sporn MB, Roberts AB. Antibodies to transforming growth factor-β2 peptides: Specific detection of TGF-β2 in immunoassays Growth Factors. 3: 45-52. PMID 2383401 DOI: 10.3109/08977199009037501 |
0.301 |
|
1990 |
Casscells W, Bazoberry F, Speir E, Thompson N, Flanders K, Kondaiah P, Ferrans VJ, Epstein SE, Sporn M. Transforming growth factor-beta 1 in normal heart and in myocardial infarction. Annals of the New York Academy of Sciences. 593: 148-60. PMID 2375593 DOI: 10.1111/J.1749-6632.1990.Tb16107.X |
0.3 |
|
1990 |
Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 Nature. 346: 371-374. PMID 2374609 DOI: 10.1038/346371A0 |
0.33 |
|
1990 |
Kim SJ, Kehrl JH, Burton J, Tendler CL, Jeang KT, Danielpour D, Thevenin C, Kim KY, Sporn MB, Roberts AB. Transactivation of the transforming growth factor β1 (TGF-β1) gene by human T lymphotropic virus type 1 tax: A potential mechanism for the increased production of TGF-β1 in adult T cell leukemia Journal of Experimental Medicine. 172: 121-129. PMID 2358774 DOI: 10.1084/Jem.172.1.121 |
0.323 |
|
1990 |
Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-β and the initiation of chondrogenesis and osteogenesis in the rat femur Journal of Cell Biology. 110: 2195-2207. PMID 2351696 DOI: 10.1083/Jcb.110.6.2195 |
0.308 |
|
1990 |
Roberts AB, Rosa F, Roche NS, Coligan JE, Garfield M, Rebbert ML, Kondaiah P, Danielpour D, Kehrl JH, Wahl SM, Dawid IB, Sporn MB. Isolation and characterization of TGF-β2 and TGF-β5 from medium conditioned by xenopus XTC cells Growth Factors. 2: 135-147. PMID 2340184 DOI: 10.3109/08977199009071500 |
0.373 |
|
1990 |
Jakowlew SB, Dillard PJ, Sporn MB, Roberts AB. Complementary deoxyribonucleic acid cloning of an mRNA encoding transforming growth factor- β2 from chicken embryo chondrocytes Growth Factors. 2: 123-133. PMID 2340183 DOI: 10.3109/08977199009071499 |
0.313 |
|
1990 |
Roberts AB, Kondaiah P, Rosa F, Watanabe S, Good P, Danielpour D, Roche NS, Rebbert ML, Dawid IB, Sporn MB. Mesoderm induction in Xenopus laevis distinguishes between the various TGF-beta isoforms. Growth Factors (Chur, Switzerland). 3: 277-86. PMID 2257149 DOI: 10.3109/08977199009003670 |
0.353 |
|
1990 |
Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. The Journal of Clinical Investigation. 86: 1976-84. PMID 2254455 DOI: 10.1172/Jci114932 |
0.347 |
|
1990 |
Sporn MB, Roberts AB. The transforming growth factor-betas: Past, present, and future Annals of the New York Academy of Sciences. 593: 1-6. PMID 2197958 DOI: 10.1111/J.1749-6632.1990.Tb16095.X |
0.333 |
|
1990 |
Schwarz LC, Wright JA, Gingras MC, Kondaiah P, Danielpour D, Pimentel M, Sporn MB, Greenberg AH. Aberrant TGF-beta production and regulation in metastatic malignancy. Growth Factors (Chur, Switzerland). 3: 115-27. PMID 2169772 DOI: 10.3109/08977199009108274 |
0.357 |
|
1990 |
Wilder RL, Lafyatis R, Roberts AB, Case JP, Kumkumian GK, Sano H, Sporn MB, Remmers EF. Transforming growth factor-beta in rheumatoid arthritis. Annals of the New York Academy of Sciences. 593: 197-207. PMID 2165375 DOI: 10.1111/J.1749-6632.1990.Tb16112.X |
0.324 |
|
1990 |
Van Obberghen-Schilling E, Thompson NL, Flanders KC, Sporn MB, Lambert PF, Baker CC. Transforming growth factor-beta expression in fibropapillomas induced by bovine papillomavirus type 1, in normal bovine skin, and in BPV-1-transformed cells. Growth Factors (Chur, Switzerland). 2: 111-21. PMID 2160257 DOI: 10.3109/08977199009071498 |
0.365 |
|
1990 |
Glick AB, Danielpour D, Morgan D, Sporn MB, Yuspa SH. Induction and autocrine receptor binding of transforming growth factor-β2 during terminal differentiation of primary mouse keratinocytes Molecular Endocrinology. 4: 46-52. PMID 2157977 DOI: 10.1210/Mend-4-1-46 |
0.34 |
|
1990 |
Birchenall-Roberts MC, Ruscetti FW, Kasper J, Lee HD, Friedman R, Geiser A, Sporn MB, Roberts AB, Kim SJ. Transcriptional regulation of the transforming growth factor beta 1 promoter by v-src gene products is mediated through the AP-1 complex. Molecular and Cellular Biology. 10: 4978-83. PMID 2117705 DOI: 10.1128/Mcb.10.9.4978 |
0.372 |
|
1990 |
Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, Karin M, Roberts AB. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Molecular and Cellular Biology. 10: 1492-7. PMID 2108318 DOI: 10.1128/Mcb.10.4.1492 |
0.354 |
|
1990 |
Remmers EF, Lafyatis R, Kumkumian GK, Case JP, Roberts AB, Sporn MB, Wilder RL. Cytokines and growth regulation of synoviocytes from patients with rheumatoid arthritis and rats with streptococcal cell wall arthritis. Growth Factors Journal. 2: 179-188. DOI: 10.3109/08977199009071504 |
0.345 |
|
1990 |
SCHWARZ LC, WRIGHT JA, HALL A, PIMENTEL M, CHAN A, SPORN M, GREENBERG AH. Enhanced Secretion of Activated TGF-?1 and Post-Receptor Blockade to TGF-?1 Signaling in Highly Malignant Fibrosarcomas Annals of the New York Academy of Sciences. 593: 315-317. DOI: 10.1111/J.1749-6632.1990.Tb16129.X |
0.339 |
|
1990 |
COLLETTA AA, WAKEFIELD LM, BAUM M, SPORN M. Autocrine TGF? Synthesis by T47D Breast Cancer Cells in Response to a Novel Synthetic Progestin Annals of the New York Academy of Sciences. 593: 298-298. DOI: 10.1111/J.1749-6632.1990.Tb16123.X |
0.328 |
|
1989 |
Danielpour D, Dart LL, Flanders KC, Roberts AB, Sporn MB. Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-β1 and TGF-β2) secreted by cells in culture Journal of Cellular Physiology. 138: 79-86. PMID 2910889 DOI: 10.1002/Jcp.1041380112 |
0.331 |
|
1989 |
Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. The Journal of Clinical Investigation. 83: 1267-76. PMID 2784799 DOI: 10.1172/Jci114011 |
0.391 |
|
1989 |
Roberts AB, Sporn MB. Regulation of endothelial cell growth, architecture, and matrix synthesis by TGF-β American Review of Respiratory Disease. 140: 1126-1128. PMID 2679267 DOI: 10.1164/Ajrccm/140.4.1126 |
0.352 |
|
1989 |
Sporn MB, Roberts AB. Transforming Growth Factor—β: Multiple Actions and Potential Clinical Applications Jama: the Journal of the American Medical Association. 262: 938-941. PMID 2666683 DOI: 10.1001/Jama.262.7.938 |
0.36 |
|
1989 |
Glick AB, Flanders KC, Danielpour D, Yuspa SH, Sporn MB. Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis Cell Regulation. 1: 87-97. PMID 2519621 DOI: 10.1091/Mbc.1.1.87 |
0.376 |
|
1988 |
Rosa F, Roberts AB, Danielpour D, Dart LL, Sporn MB, Dawid IB. Mesoderm induction in amphibians: the role of TGF-beta 2-like factors. Science (New York, N.Y.). 239: 783-5. PMID 3422517 DOI: 10.1126/Science.3422517 |
0.381 |
|
1988 |
Gabrielson EW, Gerwin BI, Harris CC, Roberts AB, Sporn MB, Lechner JF. Stimulation of DNA synthesis in cultured primary human mesothelial cells by specific growth factors. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 2: 2717-21. PMID 3260881 DOI: 10.1096/Fasebj.2.11.3260881 |
0.369 |
|
1988 |
Madtes DK, Raines EW, Sakariassen KS, Assoian RK, Sporn MB, Bell GI, Ross R. Induction of transforming growth factor-alpha in activated human alveolar macrophages. Cell. 53: 285-93. PMID 3258795 DOI: 10.1016/0092-8674(88)90390-X |
0.331 |
|
1988 |
Wakefield LM, Thompson NL, Flanders KC, O'Connor-McCourt MD, Sporn MB. Transforming growth factor-beta: multifunctional regulator of cell growth and phenotype. Annals of the New York Academy of Sciences. 551: 290-7; discussion 29. PMID 3245671 DOI: 10.1111/J.1749-6632.1988.Tb22355.X |
0.35 |
|
1988 |
Jakowlew SB, Dillard PJ, Sporn MB, Roberts AB. Nucleotide sequence of chicken transforming growth factor-beta 1 (TGF-β 1) Nucleic Acids Research. 16: 8730. PMID 3166520 DOI: 10.1093/Nar/16.17.8730 |
0.341 |
|
1988 |
Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors (Chur, Switzerland). 1: 91-9. PMID 3078566 DOI: 10.3109/08977198809000251 |
0.316 |
|
1988 |
Roberts AB, Flanders KC, Kondaiah P, Thompson NL, Van Obberghen-Schilling E, Wakefield L, Rossi P, de Crombrugghe B, Heine U, Sporn MB. Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Progress in Hormone Research. 44: 157-97. PMID 3064207 DOI: 10.1016/B978-0-12-571144-9.50010-7 |
0.324 |
|
1988 |
Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor-beta: possible roles in carcinogenesis. British Journal of Cancer. 57: 594-600. PMID 3044431 DOI: 10.1038/Bjc.1988.135 |
0.374 |
|
1988 |
Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-β Nature. 334: 260-262. PMID 3041283 DOI: 10.1038/334260A0 |
0.345 |
|
1988 |
Mulé JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells Cancer Immunology Immunotherapy. 26: 95-100. PMID 2452015 DOI: 10.1007/Bf00205600 |
0.394 |
|
1988 |
Flanders KC, Heine UI, Thompson NL, Wakefield LM, Sporn MB, Roberts AB. Transforming growth factor-beta - mediator of carcinogenesis, inflammation and embryonic development Fresenius Zeitschrift Fur Analytische Chemie. 330: 308. DOI: 10.1007/Bf00469222 |
0.353 |
|
1987 |
Falanga V, Tiegs SL, Alstadt SP, Roberts AB, Sporn MB. Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. The Journal of Investigative Dermatology. 89: 100-4. PMID 3496398 DOI: 10.1111/1523-1747.Ep12580445 |
0.372 |
|
1987 |
Cromack DT, Sporn MB, Roberts AB, Merino MJ, Dart LL, Norton JA. Transforming growth factor beta levels in rat wound chambers. The Journal of Surgical Research. 42: 622-8. PMID 3473269 DOI: 10.1016/0022-4804(87)90005-9 |
0.329 |
|
1987 |
Watanabe S, Lazar E, Sporn MB. Transformation of normal rat kidney (NRK) cells by an infectious retrovirus carrying a synthetic rat type α transforming growth factor gene Proceedings of the National Academy of Sciences of the United States of America. 84: 1258-1262. PMID 3469667 DOI: 10.1073/Pnas.84.5.1258 |
0.328 |
|
1987 |
Heine U, Munoz EF, Flanders KC, Ellingsworth LR, Lam HY, Thompson NL, Roberts AB, Sporn MB. Role of transforming growth factor-beta in the development of the mouse embryo. The Journal of Cell Biology. 105: 2861-76. PMID 3320058 DOI: 10.1083/Jcb.105.6.2861 |
0.345 |
|
1987 |
Roberts AB, Sporn MB. Transforming growth factor-beta: Potential common mechanisms mediating its effects on embryogenesis, inflammation-repair and carcinogenesis Nuclear Medicine and Biology. 14: 435-439. PMID 3308784 DOI: 10.1016/0883-2897(87)90020-1 |
0.388 |
|
1987 |
Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, Ross R, Sporn MB. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proceedings of the National Academy of Sciences of the United States of America. 84: 6020-4. PMID 2888109 DOI: 10.1073/Pnas.84.17.6020 |
0.383 |
|
1987 |
Wakefield LM, Smith DM, Masui T, Harris CC, Sporn MB. Distribution and modulation of the cellular receptor for transforming growth factor-beta. The Journal of Cell Biology. 105: 965-75. PMID 2887577 DOI: 10.1083/Jcb.105.2.965 |
0.368 |
|
1987 |
Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proceedings of the National Academy of Sciences of the United States of America. 84: 5788-92. PMID 2886992 DOI: 10.1073/Pnas.84.16.5788 |
0.377 |
|
1987 |
Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science (New York, N.Y.). 237: 1333-6. PMID 2442813 DOI: 10.1126/Science.2442813 |
0.338 |
|
1986 |
Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor factor-β: Biological function and chemical structure Science. 233: 532-534. PMID 3487831 DOI: 10.1126/Science.3487831 |
0.333 |
|
1986 |
Assoian RK, Sporn MB. Type β transforming growth factor in human platelets: Release during platelet degranulation and action on vascular smooth muscle cells Journal of Cell Biology. 102: 1217-1223. PMID 3457014 DOI: 10.1083/Jcb.102.4.1217 |
0.346 |
|
1986 |
Anzano MA, Roberts AB, Sporn MB. Anchorage-independent growth of primary rat embryo cells is induced by platelet-derived growth factor and inhibited by type-beta transforming growth factor Journal of Cellular Physiology. 126: 312-318. PMID 3455929 DOI: 10.1002/Jcp.1041260223 |
0.367 |
|
1986 |
Sporn MB, Roberts AB, Roche NS, Kagechika H, Shudo K. Mechanism of action of retinoids. Journal of the American Academy of Dermatology. 15: 756-64. PMID 3021829 DOI: 10.1016/S0190-9622(86)70231-4 |
0.385 |
|
1986 |
Fanger BO, Wakefield LM, Sporn MB. Structure and properties of the cellular receptor for transforming growth factor type β Biochemistry. 25: 3083-3091. PMID 2873833 DOI: 10.1021/Bi00359A003 |
0.332 |
|
1986 |
Masui T, Wakefield LM, Lechner JF, LaVeck MA, Sporn MB, Harris CC. Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 83: 2438-42. PMID 2871553 DOI: 10.1073/Pnas.83.8.2438 |
0.393 |
|
1986 |
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. The Journal of Experimental Medicine. 163: 1037-50. PMID 2871125 DOI: 10.1084/Jem.163.5.1037 |
0.355 |
|
1986 |
Fanger BO, Sporn MB. A binding assay for the solubilized receptors of type beta transforming growth factor: Adsorption and removal of free ligand by dextran-coated charcoal Analytical Biochemistry. 156: 444-453. PMID 2429585 DOI: 10.1016/0003-2697(86)90278-2 |
0.325 |
|
1986 |
Roberts AB, Sporn MB, Assoian RK. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro Proceedings of the National Academy of Sciences of the United States of America. 83: 4167-4171. PMID 2424019 DOI: 10.1073/Pnas.83.12.4167 |
0.357 |
|
1985 |
Sporn MB, Roberts AB. Autocrine growth factors and cancer Nature. 313: 745-747. PMID 3883191 DOI: 10.1038/313745A0 |
0.329 |
|
1985 |
Smith JM, Sporn MB, Roberts AB, Derynck R, Winkler ME, Gregory H. Human transforming growth factor-alpha causes precocious eyelid opening in newborn mice. Nature. 315: 515-6. PMID 3873618 DOI: 10.1038/315515A0 |
0.32 |
|
1985 |
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proceedings of the National Academy of Sciences of the United States of America. 82: 119-23. PMID 3871521 DOI: 10.1073/Pnas.82.1.119 |
0.393 |
|
1985 |
Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 316: 701-5. PMID 3861940 DOI: 10.1038/316701A0 |
0.361 |
|
1985 |
Anzano MA, Roberts AB, De Larco JE, Wakefield LM, Assoian RK, Roche NS, Smith JM, Lazarus JE, Sporn MB. Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Molecular and Cellular Biology. 5: 242-7. PMID 3856735 DOI: 10.1128/Mcb.5.1.242 |
0.347 |
|
1985 |
Dart LL, Smith DM, Meyers CA, Sporn MB, Frolik CA. Transforming growth factors from a human tumor cell: Characterization of transforming growth factor β and identification of high molecular weight transforming growth factor α Biochemistry. 24: 5925-5931. PMID 3002426 DOI: 10.1021/Bi00342A035 |
0.352 |
|
1985 |
Roberts AB, Roche NS, Sporn MB. Selective inhibition of the anchorage-independent growth of myc-transfected fibroblasts by retinoic acid Nature. 315: 237-239. PMID 2987698 DOI: 10.1038/315237A0 |
0.372 |
|
1984 |
Frolik CA, Roller PP, Cone JL, Dart LL, Smith DM, Sporn MB. Inhibition of transforming growth factor-induced cell growth in soft agar by oxidized polyamines. Archives of Biochemistry and Biophysics. 230: 93-102. PMID 6585180 DOI: 10.1016/0003-9861(84)90089-4 |
0.374 |
|
1984 |
Assoian RK, Grotendorst GR, Miller DM, Sporn MB. Cellular transformation by coordinated action of three peptide growth factors from human platelets Nature. 309: 804-806. PMID 6330562 DOI: 10.1038/309804A0 |
0.35 |
|
1984 |
Assoian RK, Frolik CA, Roberts AB, Miller DM, Sporn MB. Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell. 36: 35-41. PMID 6319010 DOI: 10.1016/0092-8674(84)90071-0 |
0.379 |
|
1983 |
Anzano MA, Roberts AB, Smith JM, Sporn MB, De Larco JE. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proceedings of the National Academy of Sciences of the United States of America. 80: 6264-8. PMID 6604914 DOI: 10.1073/Pnas.80.20.6264 |
0.361 |
|
1983 |
Frolik CA, Dart LL, Meyers CA, Smith DM, Sporn MB. Purification and initial characterization of a type β transforming growth factor from human placenta Proceedings of the National Academy of Sciences of the United States of America. 80: 3676-3680. PMID 6602340 DOI: 10.1073/Pnas.80.12.3676 |
0.354 |
|
1983 |
Sporn MB, Roberts AB, Shull JH, Smith JM, Ward JM, Sodek J. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science (New York, N.Y.). 219: 1329-31. PMID 6572416 DOI: 10.1126/Science.6572416 |
0.308 |
|
1983 |
Sporn MB. Retinoids and suppression of carcinogenesis Hospital Practice. 18: 83-98. PMID 6413381 DOI: 10.1080/21548331.1983.11702658 |
0.33 |
|
1983 |
Sporn MB. Role of Retinoids in Differentiation and Carcinogenesis Cancer Research. 43: 3034-3040. PMID 6189589 DOI: 10.1093/Jnci/73.6.1381 |
0.346 |
|
1982 |
Anzano MA, Roberts AB, Smith JM, Lamb LC, Sporn MB. Purification by reverse-phase high-performance liquid chromatography of an epidermal growth factor-dependent transforming growth factor. Analytical Biochemistry. 125: 217-24. PMID 6983313 DOI: 10.1016/0003-2697(82)90405-5 |
0.335 |
|
1982 |
Roberts AB, Anzano MA, Lamb LC, Smith JM, Frolik CA, Marquardt H, Todaro GJ, Sporn MB. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature. 295: 417-9. PMID 6276769 DOI: 10.1038/295417A0 |
0.369 |
|
1981 |
Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proceedings of the National Academy of Sciences of the United States of America. 78: 5339-43. PMID 6975480 DOI: 10.1073/Pnas.78.9.5339 |
0.37 |
|
1981 |
Todaro GJ, De Larco JE, Fryling C, Johnson PA, Sporn MB. Transforming growth factors (TGFs): properties and possible mechanisms of action. Journal of Supramolecular Structure and Cellular Biochemistry. 15: 287-301. PMID 6267317 DOI: 10.1002/Jsscb.1981.380150306 |
0.365 |
|
1980 |
Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. The New England Journal of Medicine. 303: 878-80. PMID 7412807 DOI: 10.1056/Nejm198010093031511 |
0.308 |
|
1980 |
Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proceedings of the National Academy of Sciences of the United States of America. 77: 3494-8. PMID 6251462 DOI: 10.1073/Pnas.77.6.3494 |
0.334 |
|
1978 |
Todaro GJ, De Larco JE, Sporn MB. Retinoids block phenotypic cell transformation produced by sarcoma growth factor Nature. 276: 272-274. PMID 213728 DOI: 10.1038/276272A0 |
0.374 |
|
1977 |
Moon RC, Grubbs CJ, Sporn MB, Goodman DG. Retinyl acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea [16] Nature. 267: 620-621. PMID 876383 DOI: 10.1038/267620A0 |
0.327 |
|
Show low-probability matches. |